Alberto Russu

493 total citations
30 papers, 352 citations indexed

About

Alberto Russu is a scholar working on Psychiatry and Mental health, Statistics and Probability and Physiology. According to data from OpenAlex, Alberto Russu has authored 30 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Psychiatry and Mental health, 8 papers in Statistics and Probability and 7 papers in Physiology. Recurrent topics in Alberto Russu's work include Schizophrenia research and treatment (8 papers), Statistical Methods in Clinical Trials (7 papers) and Alzheimer's disease research and treatments (6 papers). Alberto Russu is often cited by papers focused on Schizophrenia research and treatment (8 papers), Statistical Methods in Clinical Trials (7 papers) and Alzheimer's disease research and treatments (6 papers). Alberto Russu collaborates with scholars based in Belgium, United States and United Kingdom. Alberto Russu's co-authors include Johannes Streffer, Luc Tritsmans, Maarten Timmers, Luc Van Nueten, Sebastiaan Engelborghs, Mahesh N. Samtani, Ina Tesseur, Jennifer Bogert, H. Robert Brashear and An Vermeulen and has published in prestigious journals such as IEEE Transactions on Biomedical Engineering, Clinical Pharmacology & Therapeutics and Clinical Pharmacokinetics.

In The Last Decade

Alberto Russu

26 papers receiving 346 citations

Peers

Countries citing papers authored by Alberto Russu

Since Specialization

Citations

This map shows the geographic impact of Alberto Russu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alberto Russu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alberto Russu more than expected).

Fields of papers citing papers by Alberto Russu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alberto Russu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alberto Russu. The network helps show where Alberto Russu may publish in the future.

Co-authorship network of co-authors of Alberto Russu

This figure shows the co-authorship network connecting the top 25 collaborators of Alberto Russu. A scholar is included among the top collaborators of Alberto Russu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alberto Russu. Alberto Russu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Population Pharmacokinetics of Niraparib/Abiraterone Acetate Administered as Single-Agent Combination and Dual-Acting Tablets Plus Prednisone for Metastatic Castration-Resistant Prostate Cancer 2025 ·Advances in Therapy ·Alberto Russu, Anasuya Hazra, Hui Tian, Nahor Haddish‐Berhane, Juan José Pérez Ruixo, (unknown)	0
2	Population pharmacokinetics of selexipag for dose selection and confirmation in pediatric patients with pulmonary arterial hypertension 2024 ·CPT Pharmacometrics & Systems Pharmacology ·Lene Nygaard Axelsen, Anne Kümmel, Juan José Pérez Ruixo, Alberto Russu	0
3	Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation 2024 ·Clinical Pharmacokinetics ·Alex Yu, Anasuya Hazra, James Jiao, Peter Hellemans, (unknown), Hui Tian, Juan José Pérez Ruixo, Nahor Haddish‐Berhane, Danièle Ouellet, Alberto Russu	1
4	Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I) 2024 ·European Journal of Drug Metabolism and Pharmacokinetics ·Huybrecht T’jollyn, Alberto Russu, Raja Venkatasubramanian, Srihari Gopal, Partha Nandy, (unknown), (unknown), Mahesh N. Samtani, (unknown), Juan José Pérez Ruixo	1
5	Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II) 2024 ·European Journal of Drug Metabolism and Pharmacokinetics ·Huybrecht T’jollyn, Raja Venkatasubramanian, (unknown), Srihari Gopal, Alberto Russu, Partha Nandy, Juan José Pérez Ruixo, (unknown)	3
6	Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non‐Small Cell Lung Cancer 2023 ·Clinical Pharmacology & Therapeutics ·Nahor Haddish‐Berhane, (unknown), Alberto Russu, Meena Thayu, Roland E. Knoblauch, (unknown), John Xie, (unknown), Yu‐Nien Sun, Honghui Zhou	5
7	Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study 2020 ·Alzheimer s Research & Therapy ·Gerald Novak, Johannes Streffer, Maarten Timmers, David Henley, H. Robert Brashear, Jennifer Bogert, Alberto Russu, Luc Janssens, Ina Tesseur, Luc Tritsmans, Luc Van Nueten, Sebastiaan Engelborghs	73
8	Bayesian sequential integration within a preclinical pharmacokinetic and pharmacodynamic modeling framework: Lessons learned 2019 ·Pharmaceutical Statistics ·(unknown), Tom Jacobs, Helena Geys, Thomas Jaki, Jan Serroyen, Moreno Ursino, Alberto Russu, Christel Faes	4
9	Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations 2019 ·Journal of Clinical Psychopharmacology ·Alberto Russu, Adam Savitz, Maju Mathews, Srihari Gopal, (unknown), Mahesh N. Samtani	6
10	Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study 2018 ·Alzheimer s Research & Therapy ·Maarten Timmers, Johannes Streffer, Alberto Russu, (unknown), Hiroko Shimizu, (unknown), (unknown), (unknown), Anne Börjesson‐Hanson, Niels Andreasen, Jorge Matías‐Guiu, Miquel Baquero, Merçé Boada, Ina Tesseur, Luc Tritsmans, Luc Van Nueten, Sebastiaan Engelborghs	73
11	Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulations 2018 ·International Journal of Clinical Practice ·Alberto Russu, Jennifer Kern Sliwa, Paulien Ravenstijn, Arun Singh, Maju Mathews, Edward Kim, Srihari Gopal	12
12	Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data 2017 ·CNS Drugs ·(unknown), Mahesh N. Samtani, Elodie L. Plan, E. Niclas Jonsson, Stefaan Rossenu, An Vermeulen, Alberto Russu	18
13	Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia 2016 ·Clinical Pharmacokinetics ·(unknown), Mahesh N. Samtani, Elodie L. Plan, E. Niclas Jonsson, Stefaan Rossenu, An Vermeulen, Alberto Russu	30
14	Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle 2016 ·Journal of Clinical Psychopharmacology ·Paulien Ravenstijn, Mahesh N. Samtani, Alberto Russu, David Hough, Srihari Gopal	5
15	Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer’s Disease Trials of Bapineuzumab 2016 ·Journal of Alzheimer s Disease ·Alberto Russu, Mahesh N. Samtani, Steven Xu, Omoniyi J. Adedokun, Ming Lu, Kaori Ito, Brian Corrigan, Sangeeta Raje, Enchi Liu, H. Robert Brashear, Scot Styren, Chuanpu Hu	4
16	Population model of longitudinal FEV1 data in asthmatics: meta-analysis and predictability of placebo response 2014 ·Journal of Pharmacokinetics and Pharmacodynamics ·(unknown), Alberto Russu, Shuying Yang, Giuseppe De Nicolao, Stefano Zamuner, Misba Beerahee	5
17	Stochastic model search with binary outcomes for genome-wide association studies 2012 ·Journal of the American Medical Informatics Association ·Alberto Russu, Alberto Malovini, Annibale Alessandro Puca, Riccardo Bellazzi	7
18	Joint Modeling of Efficacy, Dropout, and Tolerability in Flexible-Dose Trials: A Case Study in Depression 2012 ·Clinical Pharmacology & Therapeutics ·Alberto Russu, (unknown), Giuseppe De Nicolao, Andrew C. Hooker, Italo Poggesi, Roberto Goméni, Stefano Zamuner	7
19	Bayesian Population Modeling of Phase I Dose Escalation Studies: Gaussian Process Versus Parametric Approaches 2011 ·IEEE Transactions on Biomedical Engineering ·Alberto Russu, Italo Poggesi, Roberto Goméni, Giuseppe De Nicolao	3
20	Bayesian population approaches to the analysis of dose escalation studies 2011 ·Computer Methods and Programs in Biomedicine ·Alberto Russu, Giuseppe De Nicolao, Italo Poggesi, (unknown), Roberto Goméni	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact